An economic evaluation of breast cancer interventions in Kenya
- PMID: 39552713
- PMCID: PMC11563939
- DOI: 10.1016/j.eclinm.2024.102894
An economic evaluation of breast cancer interventions in Kenya
Abstract
Background: Cancer is the third leading cause of death in Kenya. Breast cancer is responsible for 3100 deaths annually. Quantifying the economic and social impacts of breast cancer supports inclusion of cancer care within Kenya's universal healthcare plan.
Methods: Kenya's Ministry of Health led an economic cost-benefit analysis of expanding breast cancer prevention and treatment services. Three scenarios (early diagnosis only, screening with clinical breast exam (CBE-led), and screening with mammography (MG-led)) were modelled using an adapted version of a deterministic state-transition cohort simulation model jointly developed by the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) and maintained by Forecast Health. Real world evidence on the favorable stage-shift induced by each early detection scenario was used as model inputs. The model estimated the mortality benefits of favorable stage-shifting, and net financial costs and health and economic benefits in 2020 USD.
Findings: Respectively, over 40 years, the cost to sustain early diagnosis programs only, CBE-led screening, or mammogram-led screening would require 1.4, 2.8, or 5.2 percent increases above current government health spending. All three strategies are economically efficient in the long run. Net economic benefits of expanded breast cancer care using clinical breast exam screening are $2.3 billion dollars (USD) over the next 40 years with 236,000 women's lives saved in Kenya. Mammographic screening provides net benefits of $1.9 billion (USD) with an additional 34,000 lives saved over 40 years compared to the CBE-led screening approach. Over 40 years, an early diagnosis-only strategy saves the fewest lives and has the lowest net benefit among the three strategies.
Interpretation: We offer a novel economic evaluation for breast cancer prevention and care expansion within Universal Health Coverage in Kenya. It demonstrates the economic viability of providing those services in a low-middle income (LMI) context.
Funding: The work was funded by the World Bank Group's Tackling Non-Communicable Diseases Challenges in Low- and Middle-Income Countries Trust Fund, supported by the Access Accelerated Partnership. This report was also partially financed by the Global Financing Facility for Women, Children and Adolescents (GFF). The GFF is a global multi-stakeholder partnership hosted at the World Bank that provides catalytic financing and technical support for safe and equitable delivery of essential health and nutrition services for women, children and adolescents, while helping countries to build more resilient health systems.
Keywords: Breast cancer; Economic evaluation; UHC.
© 2024 Published by Elsevier Ltd.
Conflict of interest statement
RN has no conflicts of interest. She reports consulting fees from the World Bank in association with preparation of this manuscript and NCD economic analyses. Filip Meheus reports travel fees from Penn Dental Medicine. All authors declare that they have no conflicts.
Figures
References
-
- GLOBOCAN 2020 Database . World Health Organization; 2022. International agency for research on cancer.http://gco.iarc.fr/today/home Available from:
-
- Kenya Ministry of Health . Kenya national cancer control strategy, 2023-2027. 2022.
-
- World Bank . World Bank Group; Washington, DC: 2022. Tackling NCDs in Kenya: economic evaluation of breast and cervical cancer control interventions in Kenya. Report No.: AUS0002775.
-
- Muthoni A., Miller A.N. An exploration of rural and urban Kenyan women's knowledge and attitudes regarding breast cancer and breast cancer early detection measures. Health Care Women Int. 2010;31(9):801–816. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources